These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25996963)

  • 1. The role of diabetes in acromegaly associated neoplasia.
    Cheng S; Gomez K; Serri O; Chik C; Ezzat S
    PLoS One; 2015; 10(5):e0127276. PubMed ID: 25996963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
    Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
    Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS; Musolino NR; Salgado LR; Bronstein MD
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging trends in the diagnosis and treatment of acromegaly in Canada.
    Vallette S; Ezzat S; Chik C; Ur E; Imran SA; Van Uum S; Rivera J; Caspar-Bell G; Serri O
    Clin Endocrinol (Oxf); 2013 Jul; 79(1):79-85. PubMed ID: 23190441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry.
    Fieffe S; Morange I; Petrossians P; Chanson P; Rohmer V; Cortet C; Borson-Chazot F; Brue T; Delemer B;
    Eur J Endocrinol; 2011 Jun; 164(6):877-84. PubMed ID: 21464140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic.
    Mercado M; Gonzalez B; Vargas G; Ramirez C; de los Monteros AL; Sosa E; Jervis P; Roldan P; Mendoza V; López-Félix B; Guinto G
    J Clin Endocrinol Metab; 2014 Dec; 99(12):4438-46. PubMed ID: 25210882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly.
    Espinosa-de-los-Monteros AL; Mercado M; Sosa E; Lizama O; Guinto G; Lopez-Felix B; Garcia O; Hernández I; Ovalle A; Mendoza V
    J Neurosurg; 2002 Aug; 97(2):287-92. PubMed ID: 12186455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults.
    Marzullo P; Di Somma C; Pratt KL; Khosravi J; Diamandis A; Lombardi G; Colao A; Rosenfeld RG
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3001-8. PubMed ID: 11443159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
    Peacey SR; Toogood AA; Veldhuis JD; Thorner MO; Shalet SM
    J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Outcome of somatostatin analogue treatment in acromegaly].
    Mondok A; Tóth M; Patócs A; Szücs N; Igaz P; Pusztai P; Czirják S; Beko G; Gláz E; Rácz K; Tulassay Z
    Orv Hetil; 2009 Aug; 150(31):1457-62. PubMed ID: 19617182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Acromegaly and pregnancy: report of six new cases].
    Persechini ML; Gennero I; Grunenwald S; Vezzosi D; Bennet A; Caron P
    J Gynecol Obstet Biol Reprod (Paris); 2014 Nov; 43(9):704-12. PubMed ID: 24035359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of acromegalic patients at risk of developing colonic adenomas.
    Bogazzi F; Cosci C; Sardella C; Costa A; Manetti L; Gasperi M; Rossi G; Bartalena L; Martino E
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1351-6. PubMed ID: 16449330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
    Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of neoplasms in patients with acromegaly - the need for a national registry.
    Matyjaszek-Matuszek B; Obel E; Lewicki M; Kowalczyk-Bołtuć J; Smoleń A
    Ann Agric Environ Med; 2018 Sep; 25(3):559-561. PubMed ID: 30260174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women.
    Caron P; Broussaud S; Bertherat J; Borson-Chazot F; Brue T; Cortet-Rudelli C; Chanson P
    J Clin Endocrinol Metab; 2010 Oct; 95(10):4680-7. PubMed ID: 20660047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
    Elias PC; Lugao HB; Pereira MC; Machado HR; Castro Md; Moreira AC
    Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.
    Ayuk J; Clayton RN; Holder G; Sheppard MC; Stewart PM; Bates AS
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1613-7. PubMed ID: 15070920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of malignant neoplasms in acromegaly: a case-control study.
    Wolinski K; Stangierski A; Dyrda K; Nowicka K; Pelka M; Iqbal A; Car A; Lazizi M; Bednarek N; Czarnywojtek A; Gurgul E; Ruchala M
    J Endocrinol Invest; 2017 Mar; 40(3):319-322. PubMed ID: 27770388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.